Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06485843 · ClinicalTrials.gov registry record · Phase 2
An Study to Evaluate Safety and Tolerability of OA-SYS in Subjects With Moderate to Severe Osteoarthritis of the Knee Joint
A Phase 2 study of Osteoarthritis and Osteo Arthritis Knee, sponsored by Ageless Biotech.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 400
- Enrollment target
- 1
- Study location
NCT06485843 is a Phase 2 study of Osteoarthritis and Osteo Arthritis Knee that is actively recruiting participants, run by Ageless Biotech. The registered enrollment target is 400 participants, below the 815-participant average among 135 other Osteoarthritis trials with a reported enrollment target (51% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06485843, a Phase 2 study of Osteoarthritis and Osteo Arthritis Knee, is actively recruiting participants, sponsored by Ageless Biotech.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 400 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is being conducted to evaluate the safety and tolerability of OA-SYS in patients with moderate to severe OA of the knee joint.
Conditions Studied
Interventions
- DRUG OA-SYS
Study Locations (1)
Nevada
- Orthopedic & Sports Medicine Institute of Las Vegas - Las Vegas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2025-05-21 |
| Est. Completion | 2028-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06485843
The ClinicalTrials.gov registry entry for NCT06485843 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 400 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 815-participant average among 135 other Osteoarthritis trials with a reported enrollment target (51% lower). The listed sponsor is Ageless Biotech, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Osteoarthritis appearing as the primary indexed condition, and to 1 intervention - of which OA-SYS is the first listed.
NCT06485843 reports 1 study location spanning 1 distinct geographic area - top geographies include Nevada.
Frequently Asked Questions
What is clinical trial NCT06485843 about?
NCT06485843 is a clinical study titled "An Study to Evaluate Safety and Tolerability of OA-SYS in Subjects With Moderate to Severe Osteoarthritis of the Knee Joint". This study is being conducted to evaluate the safety and tolerability of OA-SYS in patients with moderate to severe OA of the knee joint.
What is the current status of trial NCT06485843?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 400 participants. The study started on 2025-05-21. Estimated completion is 2028-12-31.
What conditions does trial NCT06485843 study?
This clinical trial studies the following conditions: Osteoarthritis, Osteo Arthritis Knee.
What interventions are being tested in trial NCT06485843?
The interventions under investigation include: OA-SYS (DRUG).
Who is sponsoring clinical trial NCT06485843?
This trial is sponsored by Ageless Biotech, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06485843 being conducted?
This trial has 1 study location across Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Osteoarthritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety & Effectiveness of Autologous Regenerative Cell Therapy on Pain & Inflammation of Osteoarthritis of the Knee
RECRUITING · Phase 2
-
Safety & Effectiveness of Autologous Regenerative Cell Therapy on Pain & Inflammation of Osteoarthritis of the Shoulder
RECRUITING · Phase 2
-
Safety & Effectiveness of Autologous Regenerative Cell Therapy on Pain & Inflammation of Osteoarthritis of the Hip
RECRUITING · Phase 2
-
Platelet Rich Plasma Injections In Young And Old Human Subjects
RECRUITING · Phase 2
-
A Mobile Intervention to Reduce Pain and Improve Health-III
RECRUITING · Phase 2
-
Adductor Canal Block
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.